Protalix BioTherapeutics (PLX) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.67 +1.91%
EPS Growth %: -133.3%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -133.3%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $10 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
